Clinical Trial Update: A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial in idiopathic pulmonary fibrosis is evaluating whether pirfenidone influences the blood concentration of BI-1015550. The study is spons…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• BI-1015550 (BI-1015550)
• Esbriet (pirfenidone)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: RECRUITING